The team determined to turn the tables on late-stage disease
Dr. Zhang, the CEO and founder of Yinuoke Ltd. Dr. Zhang obtained a doctoral degree in immunology from Jilin University in 2007. Following that, from 2008 to 2012, Dr. Zhang pursued a postdoctoral fellowship at Stanford School of Medicine, where the focus of their research was cancer immunology and immunotherapy.
Suzan Allen is a top pharmaceutical executive with expertise in clinical operations. She has a keen eye for identifying emerging trends and opportunities in the pharmaceutical landscape, driving the development of groundbreaking therapies. Throughout her career, Suzan has demonstrated exceptional leadership skills and a deep understanding of clinical operations.
Jeremy Barton is a highly experienced professional with over 30 years of expertise in oncology drug development. He excels in bridging preclinical research and early development, emphasizing proof of concept and precision medicine.
Dr. Hendifar pioneered specialized teams for pancreatic cancer, carcinoid tumors, and neuroendocrine tumors. Leading groundbreaking therapies, including radioimmunotherapy and anti-inflammatory treatments, he holds a medical degree from Tulane University School of Medicine, completed a residency at Los Angeles County + USC Medical Center, and a fellowship at the University of Southern California. He has collaborated with institutions like Cedars-Sinai, Beverly Cancer Care, Sarcoma Oncology Center, and USC.
Dr. Philip Bonomi, our esteemed advisor, is a renowned Chicago-based oncologist with over 20 years of experience. He is affiliated with prestigious institutions like Rush University Medical Center, Rush Oak Park Hospital, and Geisinger Health System, earning high regard in the medical community. He earned his medical degree from the University of Illinois College of Medicine at Chicago.
Dr. Guttridge, a professor at Ohio State University’s College of Medicine, specializes in NF-kB transcription factors and cell biology, particularly in cancer cachexia, pancreatic cancer, and muscle disorders like muscular dystrophy and rhabdomyosarcoma. He earned a PhD in biological sciences from UC Irvine, a master’s in biochemistry from Cal State, and gained additional expertise through a postdoc at the Lineberger Cancer Center at UNC Chapel Hill.
Tony Hunter, a distinguished professor at the Salk Institute, focuses on cell growth control mechanisms and their role in cancer. He’s made significant contributions to signal transduction, which affects cancer treatment. Hunter holds a B.A. with First Class Honors and a Ph.D. from the University of Cambridge.